| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Tafluprost |
| Brand | Saflutan® |
| Indication | For the reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension. |
| Assessment Process | |
| Rapid review commissioned | 25/03/2011 |
| Rapid review completed | 09/04/2011 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended. |
Arekibo
Tapentadol (Palexia®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Tapentadol |
| Brand | Palexia® |
| Indication | For the management of adult patients with severe chronic/acute pain. |
| Assessment Process | |
| Rapid review commissioned | 19/10/2010 |
| Rapid review completed | 22/10/2020 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/01/2011 |
| NCPE assessment completed | 08/04/2011 |
| NCPE assessment outcome | Reimbursement Recommended |
Tapentadol (Palexia®) may be considered cost-effective but should be reserved for patients who cannot tolerate existing strong oral opioids.
Technology
In pharmacoeconomic evaluation, ‘technology’ is used to mean a drug or other treatment that is being assessed.
Telaprevir (Incivo®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Telaprevir |
| Brand | Incivo® |
| Indication | As add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1. |
| Assessment Process | |
| Rapid review commissioned | 28/10/2011 |
| Rapid review completed | 02/11/2011 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 08/11/2011 |
| NCPE assessment completed | 19/01/2012 |
| NCPE assessment outcome | Reimbursement Recommended |
We consider telaprevir (Incivo®) a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting.
Ticagrelor (Brilique®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Ticagrelor |
| Brand | Brilique® |
| Indication | For the prevention of atherothrombotic events in adult patients with Acute Coronary Syndrome (ACS) including patients managed medically, and those who are managed with PCI (Percutaneous Coronary Intervention) or CABG (Coronary Artery Bypass Graft). |
| Assessment Process | |
| Rapid review commissioned | 25/11/2010 |
| Rapid review completed | 20/01/2011 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/07/2011 |
| NCPE assessment completed | 10/10/2011 |
| NCPE assessment outcome | Reimbursement Recommended |
We consider Ticagrelor (Brilique®) a cost effective therapy for the prevention of atherothrombotic events in adult patients with ACS including patients managed medically and those managed with PCI or CABG.
Time Horizon
Period of time over which costs and outcomes are measured in economic evaluation.
Tobramycin (TOBI Podhaler®)
| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Tobramycin |
| Brand | TOBI Podhaler® |
| Indication | For the suppressive therapy of chronic pulmonary infection due to Ps aeruginosa in adults and children aged 6 years and older with CF. |
| Assessment Process | |
| Rapid review commissioned | 03/11/2010 |
| Rapid review completed | 29/11/2010 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
Transition Probability
The probability that the health of a patient changes from one health state to another health state within a given period
Uncertainty
a state in which the true value of a parameter or the structure of a process is unknown
Universal Infant Hepatitis B Vaccination programme
Cost effectiveness analysis of a universal infant hepatitis B vaccination programme in Ireland
In October 2006, the National Centre for Pharmacoeconomics conducted an economic evaluation of the cost-effectiveness of a universal hepatitis B vaccination programme, for the Health Protection Surveillance Centre/National Immunisation Advisory Committee. A summary of the main findings are available in the attached document.
Ustekinumab (Stelara®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Ustekinumab |
| Brand | Stelara® |
| Indication | For the treatment of moderate to severe psoriasis. |
| Assessment Process | |
| Full submission received from Applicant | 01/07/2009 |
| NCPE assessment completed | 01/11/2009 |
| NCPE assessment outcome | Reimbursement recommended. |
We consider ustekinumab cost effective for the treatment of moderate to severe plaque psoriasis in the Irish healthcare setting.
Utility
A measure of preference for a specific health outcome, obtained by methods that involve uncertainty (e.g., standard gamble approach). Utilities are usually expressed on a cardinal scale of zero to one (e.g. death typically has a utility value of zero and a full healthy life has a value of one) and are used as health-related quality of life weights to calculate QALYs.
Value-of-information (VOI)
value-of-information techniques assess the expected costs of uncertainty surrounding a decision made on the basis of current information, in order to determine whether further research should be conducted and how this should be designed.
Velaglucerase Alfa (VPRIV®)
| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Velaglucerase Alfa |
| Brand | VPRIV® |
| Indication | For long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease. |
| Assessment Process | |
| Rapid review commissioned | 26/04/2011 |
| Rapid review completed | 20/06/2011 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.
Vemurafenib (Zelboraf®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Vemurafenib |
| Brand | Zelboraf® |
| Indication | For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. |
| Assessment Process | |
| Rapid review commissioned | 23/12/2011 |
| Rapid review completed | 04/01/2012 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 04/05/2012 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price |
The NCPE believe that, at the submitted price, vemurafenib (Zelboraf®) is not cost effective for this indication
September 2014
The HSE has approved reimbursement following confidential price negotiations.
Vernakalant (Brinavess®)
| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Vernakalant |
| Brand | Brinavess® |
| Indication | For haemodynamically stable, symptomatic patients with atrial fibrillation of less than 48 hours duration. |
| Assessment Process | |
| Rapid review commissioned | 26/10/2010 |
| Rapid review completed | 04/11/2010 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 08/04/2011 |
| NCPE assessment completed | 04/05/2011 |
| NCPE assessment outcome | Reimbursement Recommended in Hospital Setting. |
Following review, we recommend reimbursement of vernakalant in the hospital setting.
Willingness-to-pay (WTP)
Evaluation method used to determine the maximum amount of money an individual is willing to pay for a particular outcome or benefit (e.g. to receive a health care service). This method is often used in cost-benefit analysis to quantify outcome in monetary terms.